Is Monopar Therapeutics Inc (MNPR) undervalued? · $431.4M cap
Monopar Therapeutics Inc (MNPR) is a biotechnology company listed on US.
This page asks whether Monopar Therapeutics Inc (MNPR) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported MNPR revenue for 2024-12-31 was $0. Net income was -$15.6M. MNPR currently screens at market cap $431.4M.
MNPR currently screens at market cap $431.4M. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new MNPR 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare MNPR to the stock page model before you treat a low multiple as a gift.
Not investment advice.